Georgina V Long

Summary

Publications

  1. pmc Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling
    Andy J Chien
    Division of Dermatology, University of Washington Department of Medicine, Seattle, Washington, United States of America The Group Health Research Institute, Seattle, Washington, United States of America
    PLoS ONE 9:e94748. 2014
  2. doi Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
    Georgina V Long
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:499-508. 2013
  3. doi Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
    Georgina V Long
    Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Rd, North Sydney, NSW 2060, Australia
    Am J Surg Pathol 37:61-5. 2013
  4. doi Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    Georgina V Long
    Melanoma Institute Australia, Westmead Institute for Cancer Research, and Westmead Hospital, The University of Sydney, Sydney, NSW, Australia
    Lancet Oncol 13:1087-95. 2012
  5. doi Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
  6. doi Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
    James S Wilmott
    Melanoma Institute Australia, Sydney, NSW, Australia
    Clin Cancer Res 18:1386-94. 2012
  7. ncbi Intrapatient homogeneity of BRAFV600E expression in melanoma
    Alexander M Menzies
    Melanoma Institute Australia Discipline of Medicine Pathology Surgery, The University of Sydney Departments of Melanoma and Surgical Oncology Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital Department of Medicine, Westmead Hospital Westmead Institute for Cancer Research, Westmead Hospital The Kinghorn Cancer Centre, Garvan Institute of Medical Research St Vincent s Clinical School, University of New South Wales, Sydney, Australia
    Am J Surg Pathol 38:377-82. 2014
  8. doi Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment
    James S Wilmott
    Melanoma Institute Australia, Sydney, New South Wales 2060, Australia
    J Immunol 192:2505-13. 2014
  9. doi BRAF inhibitor activity in V600R metastatic melanoma
    Oliver Klein
    Melanoma Institute Australia and Westmead Hospital, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales, Australia
    Eur J Cancer 49:1073-9. 2013
  10. doi Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia
    Clin Cancer Res 18:3242-9. 2012

Collaborators

Detail Information

Publications30

  1. pmc Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling
    Andy J Chien
    Division of Dermatology, University of Washington Department of Medicine, Seattle, Washington, United States of America The Group Health Research Institute, Seattle, Washington, United States of America
    PLoS ONE 9:e94748. 2014
    ..Understanding these pathway interactions will be necessary to facilitate efforts to individualize therapies for melanoma patients. ..
  2. doi Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
    Georgina V Long
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:499-508. 2013
    ..The addition of therapies targeting the cell cycle machinery may improve the response and duration of BRAFi, and investigation of the mechanisms of apoptosis may provide additional therapeutic targets. ..
  3. doi Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
    Georgina V Long
    Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Rd, North Sydney, NSW 2060, Australia
    Am J Surg Pathol 37:61-5. 2013
    ..Clinical use of the V600E BRAF antibody should be a valuable supplement to conventional mutation testing and allow V600E mutant metastatic melanoma patients to be triaged rapidly into appropriate treatment pathways...
  4. doi Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    Georgina V Long
    Melanoma Institute Australia, Westmead Institute for Cancer Research, and Westmead Hospital, The University of Sydney, Sydney, NSW, Australia
    Lancet Oncol 13:1087-95. 2012
    ..We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain...
  5. doi Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
    ..To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome...
  6. doi Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma
    James S Wilmott
    Melanoma Institute Australia, Sydney, NSW, Australia
    Clin Cancer Res 18:1386-94. 2012
    ..To evaluate the effects of treatment with the potent mutant BRAF inhibitors GSK2118436 or vemurafenib (PLX4720) on immune responses to metastatic melanoma in tissues taken before and after treatment...
  7. ncbi Intrapatient homogeneity of BRAFV600E expression in melanoma
    Alexander M Menzies
    Melanoma Institute Australia Discipline of Medicine Pathology Surgery, The University of Sydney Departments of Melanoma and Surgical Oncology Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital Department of Medicine, Westmead Hospital Westmead Institute for Cancer Research, Westmead Hospital The Kinghorn Cancer Centre, Garvan Institute of Medical Research St Vincent s Clinical School, University of New South Wales, Sydney, Australia
    Am J Surg Pathol 38:377-82. 2014
    ....
  8. doi Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment
    James S Wilmott
    Melanoma Institute Australia, Sydney, New South Wales 2060, Australia
    J Immunol 192:2505-13. 2014
    ..Further studies are needed to determine if CXCL8 is predictive of response and to confirm the functions of these chemokine and cytokine in BRAF-mutant melanoma under BRAF inhibition. ..
  9. doi BRAF inhibitor activity in V600R metastatic melanoma
    Oliver Klein
    Melanoma Institute Australia and Westmead Hospital, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales, Australia
    Eur J Cancer 49:1073-9. 2013
    ..Our experience suggests that patients with V600R BRAF mutations can be treated successfully with oral BRAF inhibitors, and molecular diagnostic assays should include detection of this type of mutation...
  10. doi Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia
    Clin Cancer Res 18:3242-9. 2012
    ..Methods: A prospectively assembled cohort of Australian patients were followed from diagnosis of metastatic melanoma (N = 308). Clinicopathologic variables were correlated with BRAF mutational status, genotype, and survival...
  11. doi Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine
    James S Wilmott
    Melanoma Institute Australia, Australia
    Mol Cancer Ther 11:2704-8. 2012
    ....
  12. pmc Dabrafenib and its potential for the treatment of metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    Drug Des Devel Ther 6:391-405. 2012
    ..It is expected that new combinations of targeted drugs, such as the combination of dabrafenib and trametinib (GSK1120212, a MEK inhibitor), will provide higher response rates and more durable clinical benefit than dabrafenib monotherapy...
  13. ncbi Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib
    Mary W F Azer
    Westmead Hospital, Westmead, Australia Melanoma Institute Australia, Sydney, Australia
    Cancer 120:530-6. 2014
    ..This study sought to examine the intracranial (IC) and extracranial (EC) patterns of response and progression in patients with active melanoma brain metastases treated with dabrafenib...
  14. ncbi Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
    Matteo S Carlino
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia
    Mol Oncol 8:544-54. 2014
    ..Our data indicate that a broader targeting strategy concurrently inhibiting ERK, rather than MEK, and PI3K/mTOR may circumvent BRAF inhibitor resistance, and should be considered during the clinical development of ERK inhibitors. ..
  15. ncbi Paradoxical oncogenesis: are all BRAF inhibitors equal?
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, NSW, Australia
    Pigment Cell Melanoma Res 26:611-5. 2013
    ....
  16. doi Incidence of new primary melanomas after diagnosis of stage III and IV melanoma
    Lisa Zimmer
    Lisa Zimmer and Dirk Schadendorf, University Hospital, University Duisburg Essen, Essen, Germany Lauren E Haydu, Alexander M Menzies, Richard A Scolyer, Richard F Kefford, John F Thompson, and Georgina V Long, Melanoma Institute Australia Alexander M Menzies, Richard A Scolyer, Richard F Kefford, and Georgina V Long, Sydney Medical School, The University of Sydney Richard A Scolyer and John F Thompson, Royal Prince Alfred Hospital Lauren E Haydu and John F Thompson, The University of Sydney John F Thompson, Mater Hospital, Sydney Richard F Kefford and Georgina V Long, Westmead Institute for Cancer Research, Westmead Hospital, Westmead, New South Wales, Australia
    J Clin Oncol 32:816-23. 2014
    ..We sought to determine the background incidence of spontaneous NPMs after a diagnosis of American Joint Committee on Cancer/International Union Against Cancer stage III or IV melanoma in patients not treated with a BRAF inhibitor...
  17. doi (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
    Matteo S Carlino
    Westmead Millennium Institute, The University of Sydney, Sydney, Australia
    Eur J Cancer 49:395-402. 2013
    ..We aim to determine the prevalence, and clinicopathologic correlates of intra-patient heterogeneity of FDG-PET response in metastatic melanoma treated with dabrafenib, and to determine whether heterogeneity predicts clinical outcome...
  18. ncbi Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma
    Rajmohan Murali
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    Cancer 118:4519-29. 2012
    ..The authors sought to address the latter question in the current study...
  19. ncbi BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact
    Helen Rizos
    Authors Affiliations Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute Departments of Medical Oncology and Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead Melanoma Institute Australia Disciplines of Pathology, Medicine, and Surgery, Sydney Medical School, The University of Sydney, Sydney Departments of Melanoma and Surgical Oncology and Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
    Clin Cancer Res 20:1965-77. 2014
    ..Multiple BRAF inhibitor resistance mechanisms have been described, however, their relative frequency, clinical correlates, and effect on subsequent therapy have not been assessed in patients with metastatic melanoma...
  20. ncbi Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma
    Matteo S Carlino
    Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia
    Mol Cancer Ther 12:1332-42. 2013
    ..These data provide a rationale for the continuation of BRAF and MEK inhibitors after disease progression and support the development of clinical trials to examine this strategy...
  21. doi Cutaneous toxicities of RAF inhibitors
    Rachael Anforth
    Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia
    Lancet Oncol 14:e11-8. 2013
    ..These disorders often affect patients' quality of life; therefore, dermatological assessment and timely management is essential to ensure that patients continue to use RAF inhibitors...
  22. doi Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma
    Rajmohan Murali
    Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
    Ann Surg Oncol 19:1782-9. 2012
    ..We sought to identify clinical and pathologic factors associated with distant metastasis and survival in a large number of patients with thin melanoma treated at a single institution...
  23. doi Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas
    Hojabr Kakavand
    1The University of Sydney, Sydney 2Melanoma Institute Australia, North Sydney 3Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 4Canterbury Health Laboratories, Christchurch, New Zealand 5Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst 6Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Pathology 46:193-8. 2014
    ..The findings have important implications for adjuvant clinical trials of targeted therapies...
  24. ncbi Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, Australia The University of Sydney, Sydney, Australia
    Eur J Cancer 49:3229-41. 2013
    ....
  25. pmc Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Sydney, Australia The University of Sydney, Sydney, Australia
    PLoS ONE 9:e85004. 2014
    ..We sought to examine the patterns of response and progression in patients treated with targeted therapy...
  26. doi Diagnosis and treatment of KIT-mutant metastatic melanoma
    Megan Lyle
    Melanoma Institute Australia, Sydney, New South Wales, Australia
    J Clin Oncol 31:3176-81. 2013
    ..However, Sanger sequencing of KIT exons 9, 11, 13, and 17, performed as screening for a clinical trial enrolling patients with metastatic acral and mucosal melanomas, showed an exon 13 K642E mutation. ..
  27. doi Treatment of melanoma brain metastases: a new paradigm
    Matteo S Carlino
    Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, Australia
    Cancer J 18:208-12. 2012
    ..We present a new treatment algorithm for melanoma patients with brain metastases, which integrates the evolving evidence for the use of BRAF inhibitors...
  28. doi Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care
    Richard A Scolyer
    Melanoma Institute Australia, Sydney, NSW, Australia
    Mol Oncol 5:124-36. 2011
    ..Whilst there remains much to be discovered in this rapidly evolving field, there is already great optimism that more rational and effective therapies for melanoma patients will soon be widely available...
  29. ncbi Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma
    Alexander M Menzies
    Authors Affiliation Melanoma Institute Australia and the University of Sydney, Sydney, Australia
    Clin Cancer Res 20:2035-43. 2014
    ..Here, we review the clinical development of both drugs as monotherapies and in combination, and discuss their role in the management of BRAF-mutant melanoma...
  30. doi The role of systemic therapies in the management of melanoma brain metastases
    Megan Lyle
    aMelanoma Institute Australia bThe University of Sydney, Sydney, Australia
    Curr Opin Oncol 26:222-9. 2014
    ..This review will focus on new systemic therapies for metastatic melanoma and their evolving role in the management of brain metastases...